Stem cell research, hailed as the future of regenerative medicine, holds immense potential for treating a myriad of diseases. However, a recent study has revealed that approximately one-fifth of stem cells grown in laboratories for medical treatments possess cancer-causing mutations. Although these cells have not been injected into humans, they are being used in research to explore their potential for medical use.

Recent studies have shown a huge variation in mutations for induced pluripotent stem cells (iPSCs), some of which severely limit their transformative abilities. Aging and evolutionary pressures cause these cells to harbor more mutations than previously suspected. Interestingly, a significant percentage of stem cell lines contained BCOR mutations predicted to be pathogenic. These mutations impaired the stem cells abilities to differentiate into other tissues, with the mutational process mainly focused on BCOR during the stem cell reprogramming process.

Despite these challenges, scientists are not deterred from exploring the potential of stem cells in cancer therapies. In a groundbreaking study, scientists from UC San Francisco and Northwestern University introduced a mutation found in cancer cells into CAR-T cells, a type of immune cell modified in the lab to fight cancer. This mutation supercharged the CAR-T cells, making them 100 times more potent against cancer cells. This innovative therapy was able to destroy solid skin, lung, and stomach tumors in mice, setting the stage for further development in human trials.

Research has also focused on the activation of lineage-inappropriate signaling pathways by leukemic stem cells (LSCs) to promote their growth. These cells aberrantly activate the VEGF and IL-5 signaling pathways, which allows them to re-enter the cell cycle while preserving self-renewal capacity. Inhibitors for VEGFA and IL5RA have shown promise in reducing proliferation, indicating these pathways as potential targets for treatment.

Further illustrating the potential of stem cells, City of Hope has reported a successful case of treating the oldest patient to achieve remission from leukemia and HIV. The patient received a blood stem cell transplant from a donor with a rare genetic mutation and was given reduced-intensity chemotherapy before the transplant. This case demonstrates the potential of stem cell transplantation in achieving remission from HIV and cancer, even in older patients.

While the presence of cancer-causing mutations in laboratory-grown stem cells poses a significant challenge, the potential breakthroughs in medical treatments such cells provide cannot be ignored. The future of regenerative medicine hinges on the successful management of these mutations and the harnessing of stem cells transformative abilities. Continued research and development in this field are essential to fully unlock the potential of stem cells for the benefit of medical science and patient care.

Read more here:
Stem Cell Research and Cancer-causing Mutations: Potential and Challenges - Medriva